Tinlarebant (LBS-008)

Name: Tinlarebant (LBS-008) in Stargardt disease type 1: Access and distribution
Published: 2026-09-14T15:39:06-04:00

Stargardt disease type 1

Manufacturer: Belite Bio
Regulatory submission: NDA submitted June 2026
Launch: Anticipated in March 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Access and distribution

2 evidence topics · 1 source

Anticipated distribution and patient support

“Specialty Pharmacy” (opens the source at this quote in a new tab)
“Prescription routed for fulfillment” (opens the source at this quote in a new tab)
“Onboarding into support programs” (opens the source at this quote in a new tab)

Anticipated patient financial support

“Financial Support Programs for Eligible Patients” (opens the source at this quote in a new tab)